ERBB2 and lung carcinoma: CUDC-101 was characterized as a multimodal inhibitor blocking simultaneously HDACs, epidermal growth factor receptor tyrosine kinase (EGFR/ErbB1), and human epidermal growth factor receptor 2 tyrosine kinase (HER2/neu or ErbB2) with potential antineoplastic activity in several breast and lung cancer cell lines [19,20].